CRF Announces TCT 2022 Late-breaking Clinical Science

CRF Announces TCT 2022 Late-breaking Clinical Science

August 4, 2022 — The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical science that will be presented at TCT 2022. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. It will take place September 16-19 in Boston, Massachusetts at the Boston Convention and Exhibition Center.

Every year, TCT features cutting-edge research in interventional cardiovascular medicine that directly impacts patient care and how physicians treat heart disease. The 32 studies selected examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that demonstrate potential to treat or prevent cardiovascular disease. Late-breaking science will be presented in the Clinical Science and Endovascular Theater and highlighted during press conferences scheduled for Saturday, September 17, Sunday, September 18, and Monday, September 19.

The full Program Guide can be found here: https://tct2022.crfconnect.com/program-guide

Saturday, September 17, 2022

Sunday, September 18, 2022

  • Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial
  • Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-year Follow-up of the SYMPLICITY HTN-3 Trial
  • Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomized Trial
  • Outcomes for the Full US Cohort of the FLASH FlowTriever Mechanical Thrombectomy Registry in Pulmonary Embolism
  • Ultrasound Guidance for Vascular Access for Cardiac Procedures: A Randomized Trial (UNIVERSAL)
  • CONFIDENCE Registry: Valve Hemodynamics and 1-Year Survival Following Implantation of the Portico Valve in Experienced TAVI Centers
  • Mediators of Improvement in TAVR Outcomes Over Time: Insights from the STS-ACC TVT Registry
  • Frequency and Safety of Bioprosthetic Valve Fracture in Patients Undergoing Valve in Valve TAVR for Failed Surgical Valves Using the SAPIEN 3/Ultra Valves: Insights From Real-World Data
  • Increased Risk of Surgical Aortic Valve Replacement After Prior Transcatheter Versus Surgical Aortic Valve Replacement
  • Cardiac Damage and Quality of Life After Aortic Valve Replacement: Results from the PARTNER Trials
  • Mid-term Echocardiographic Outcomes Following Transapical Mitral Valve Replacement: Updates from the Intrepid Pilot Study

Monday, September 19, 2022

  • Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial
  • Survival after PCI or CABG for Left Main Coronary Disease: A Report from the Swedish Coronary Angiography and Angioplasty Registry
  • A Randomized Controlled Trial Assessing the Value of Computed Tomography Cardiac Angiography (CTCA) In Improving Patient Satisfaction and Reducing Contrast Load, Procedural Duration and Complications in Patients Who Had Previous Bypass Operation (CABG) Undergoing Invasive Coronary Angiography
  • FAME 3 Substudies: Clinical Outcomes Related to Anatomic vs. Functional Significance and Prognostic Value of Post-PCI FFR
  • Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: Two-Year Outcomes of the FAVOR III China Trial
  • Randomized, Double-Blind Trial of Routine Early Treatment with PCSK-9 inhibitor in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
  • Prevention of Radial Artery Occlusion With Rivaroxaban After Transradial Coronary Procedures: The RIVARAD Multicentric Randomized Trial
  • EXpansion of Stents After Intravascular lithoTripsy Versus Conventional Predilatation in CALCified Coronary Arteries
  • Cutting Balloon to Optimize Predilatation for Stent Implantation: The COPS Randomized Trial
  • Impact of Underlying Causes of Acute Coronary Syndrome and 1-Year Outcomes After Percutaneous Coronary Intervention: Results From Optical Coherence Tomography Guided Primary Percutaneous Coronary Intervention Registry (TACTICS Registry)
  • Two-Year Outcomes of The Randomized Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) Trial

For more information: www.tctconference.com

Find more TCT22 coverage here



Source link

Leave a Reply

Your email address will not be published.

Call of Duty: Modern Warfare 2 Previous post Microsoft defends Activision Blizzard deal by saying the studio doesn’t make “must have” games
Anat Shani - CEO Synchrony Medical Next post “Synchrony is making respiratory treatment accessible for patients all around the wor